financetom
Business
financetom
/
Business
/
US to axe Biden-era 7-year deadline on exports from new LNG projects
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US to axe Biden-era 7-year deadline on exports from new LNG projects
Apr 1, 2025 1:41 PM

WASHINGTON/Houston, April 1 (Reuters) - The U.S. is

slated on Wednesday to rescind a policy issued by the

administration of former President Joe Biden that requires

liquefied natural gas, or LNG, projects to export within seven

years of receiving regulatory approval.

The LNG industry had pushed the administration of President

Donald Trump to rescind the policy statement issued in April

2023 on Department of Energy approvals for exports to big

markets in Europe and Asia because several projects require more

than seven years to complete.

"Henceforth, DOE will consider applications to extend an

authorization holder's export commencement deadline and grant

such extensions for good cause shown on a case-by-case basis, an

approach consistent with DOE's practice prior to the issuance of

the Policy Statement," said a document slated to be published in

the Federal Register on Wednesday.

Tala Goudarzi, principal deputy assistant secretary of the

Office of Fossil Energy and Carbon Management, said the Biden

administration had made it unnecessarily difficult for projects

to obtain and maintain an authorization to export LNG to

non-free-trade-agreement countries.

Pipeline operator Energy Transfer ( ET ) in 2023 filed for a

new export license for its proposed 16.45 million metric tons

per annum Lake Charles LNG facility in Louisiana, after the DOE

denied its request for a three-year extension to its old one,

saying it did not meet the criteria.

Energy Transfer ( ET ) was not immediately available for

comment.

Fred Hutchison, president and CEO of LNG Allies, a trade

group, called the previous deadline policy inflexible and said

the new policy marked a return to regular order.

"We are grateful that a commonsense approach has returned to

the U.S. LNG export process," Hutchison said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
VivoPower to Use BitGo's OTC Desk to Buy XRP Tokens
VivoPower to Use BitGo's OTC Desk to Buy XRP Tokens
Jun 2, 2025
12:02 PM EDT, 06/02/2025 (MT Newswires) -- VivoPower International ( VVPR ) will use BitGo's OTC trading desk and custody platform to build its digital asset treasury strategy as part of their partnership, the companies said Monday. VivoPower ( VVPR ), which recently reported its transition to an XRP focused treasury, will leverage the trading desk to acquire XRP for...
UiPath, HCLTech Collaborate to Advance Agentic Automation Efforts
UiPath, HCLTech Collaborate to Advance Agentic Automation Efforts
Jun 2, 2025
12:01 PM EDT, 06/02/2025 (MT Newswires) -- UiPath ( PATH ) said Monday it has formed a strategic collaboration with HCLTech to accelerate agentic automation for UiPath ( PATH ) customers globally. Financial details weren't disclosed. Under the partnership, HCLTech will leverage its AI know-how to deploy the UiPath Platform with pre-configured artificial intelligence agents and controls, enabling scalable autonomous...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
ImmunityBio Receives Expanded FDA Authorization to Treat Lymphopenia in Cancer Patients
ImmunityBio Receives Expanded FDA Authorization to Treat Lymphopenia in Cancer Patients
Jun 2, 2025
12:06 PM EDT, 06/02/2025 (MT Newswires) -- ImmunityBio ( IBRX ) shares were up nearly 6% after the company said the US Food and Drug Administration authorized expanded access to its Cancer BioShield platform and Anktiva immunotherapy to treat lymphopenia, a severe immune deficiency, in patients with solid tumors. The FDA's decision allows Anktiva to be used in patients whose...
Copyright 2023-2026 - www.financetom.com All Rights Reserved